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Abstract
Background: To characterize the human humoral immune response against enterovirus 71 (EV71) infection and
map human epitopes on the viral capsid proteins.
Methods: A series of 256 peptides spanning the capsid proteins (VP1, VP2, VP3) of BJ08 strain (genomic C4) were
synthesized. An indirect enzyme-linked immunosorbent assay (ELISA) was carried out to detect anti-EV71 IgM and
IgG in sera of infected children in acute or recovery phase. The partially overlapped peptides contained 12 amino
acids and were coated in the plate as antigen (0.1 μg/μl). Sera from rabbits immunized with inactivated BJ08 virus
were also used to screen the peptide panel.
Results: A total of 10 human anti-EV71 IgM epitopes (vp1-14 in VP1; vp2-6, 21, 40 and 50 in VP2 and vp3-10, 12,
15, 24 and 75 in VP3) were identified in acute phase sera. In contrast, only one anti-EV71 IgG epitope in VP1 (vp1-
15) was identified in sera of recovery stage. Four rabbit anti-EV71 IgG epitopes (vp1-14, 31, 54 and 71) were
identified and mapped to VP1.
Conclusion: These data suggested that human IgM epitopes were mainly mapped to VP2 and VP3 with multi-
epitope responses occurred at acute infection, while the only IgG epitope located on protein VP1 was activated in
recovery phase sera. The dynamic changes of humoral immune response at different stages of infection may have
public health significance in evaluation of EV71 vaccine immunogenicity and the clinical application of diagnostic
reagents.
Keywords: EV71, Capsid protein, Epitopes, Humoral immune response
Background
Human enterovirus 71 (EV71) is one of the major cau-
sative pathogens for human hand foot and mouth dis-
ease (HFMD). EV71 was first isolated in California in
1969. HFMD is common infectious disease frequently
occurring in infants and children. Although it usually
has no life threatening, the most severe neurological dis-
ease caused by EV71 may cause death. Therefore, EV71
is widely considered as one of the most important viru-
lent neurotropic enteroviruses after the eradication of
poliomyelitis [1].
During the last decade, outbreaks of HFMD have
occurred worldwide and the incidence rate was
significantly increased throughout the Asia-Pacific
region [2-8]. The continuing increased HFMD epidemics
in China over the last 3 years indicated HFMD has been
an important public health concern [6-8]. Due to the
absence of effective antiviral therapy for severe EV71
infections, the development of efficacious vaccine is a
top priority to effectively prevent this disease.
EV71 is a picornavirus, belonging to the type A non-
polio enteroviruses family [9]. It has a positive sense lin-
ear single stranded RNA genome of approximately 7,400
nucleotides, with a single open reading frame that
encodes 4 capsid proteins (VP1-4). VP4 is located inside
the virus capsid and connected tightly with the viral
genome. Other three proteins (VP1-3) are exposed out-
side of the capsid and consequently immunologically
reactive epitopes may reside in these proteins [10].
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develop vaccine found that majority of neutralizing anti-
body were elicited by the epitopes on VP1 protein
[11-14]. Therefore, most relevant researches have
focused on VP1 protein but neglecting the fact that VP2
and VP3 are also important components of EV71 virion.
T h e yp l a yar o l ei ne l i c i t i n gimmune responses during
infection. Until now, no human epitope has been identi-
fied on VP2 and VP3 proteins. Usually, an acute viral
infection should lead to certain epitope inducing an IgM
response, which is a significant marker for early diagno-
sis of disease, as well as for the prompt treatment of the
severe cases. However, almost all of the known epitopes
on VP1 only elicit an IgG response.
To extend the range of defined EV71 epitopes, we
employed a panel of synthetic peptides covering all
three external capsid proteins (VP1-3) as antigen to
screen IgM and IgG antibodies specifically for EV71 epi-
topes. The EV71 sera were obtained from infected chil-
dren at different stages of infectious disease (the acute
or recovery stage). Convalescent sera from rabbits were
immunized with inactivated BJ08 strain EV71 virus.
Materials and methods
Virus antigen and antigen peptides synthesis
Virus particles of EV71 BJ08 strain isolated from throat
swab samples of EV71 infected children in Beijing in
2008 [15] were inactivated as antigen for rabbit immuni-
zations. The inactivated EV71 virus with 95% purity was
kindly provided by the National Vaccine & Serum Insti-
tute (Beijing, China) at a concentration of 27.4 μg/ml.
A series of 256 overlapping peptides (each 12 amino
acids with a 9 amino acid overlapping), were synthesized
based on the deduced amino acid sequence of the VP1,
V P 2a n dV P 3p r o t e i n so fE V 7 1B J 0 8s t r a i n .T h ep u r i t y
of the synthesized peptides exceeded 70%. A peptide
from the surface antigen of Hepatitis B virus (S28-39 -
IPQSLDSWWTSL) was synthesized as a control. All
peptides were resuspended in dimethyl sulfoxide at a
c o n c e n t r a t i o no f1 0m g / m ls t o c ks o l u t i o na t- 2 0 ° C .A
fresh working solution with a final peptide concentra-
tion of 0.1 μg/ml was prepared for coating antigen.
SPF grade New Zealand White female rabbits weigh-
ing 1.75-2.25 kg were used for experiments. All animals
were purchased from Resource Center for Experimental
Animals of the National Institute for Food and Drug
Control, China.
Human sera specimens
Eight anti EV71 sera were collected from infected chil-
dren in acute stage of HFMD (defined as within 3 days
after the appearance of the first symptoms). All sera
samples were confirmed as EV71 virus positive by PCR
detection of viral RNA [16], and were verified as no
cross-reactivity for CA16 by microneutralization assay.
Eleven recovery sera samples (defined as 2 month after
illness onset) were also collected from recovered chil-
dren. All sera samples were collected by CDC in Jiangsu
Provence, China.
Sera from 4 healthy individuals with negative anti
EV71 IgM and/or IgG (screened by microneutralization
assay [17] and an in vitro indirect ELISA assay) were
used as controls in this study.
Viral RNA extraction and PCR amplification [16]
Viral RNA was extracted from clinical specimens using a
QIAamp Mini viral RNA Extraction Kit (Qiagen) according
to the manufacture’s protocol. The primers used for RT-
PCR are cited from reference 16. RT-PCR amplification was
performed using AccessQuickTM RT-PCR kit (Promega).
Cycle variables were reverse transcription at 45°C for 45
min, denaturation at 94°C for 5 min followed by 35 cycles at
95°C for 40 sec, 53°C for 40 sec, 72°C for 40 sec; and then a
final elongation step at 72°C for 5 min. The second round
amplification was performed in 25 μl volumes, which con-
tains 2.5 μl 10 × PCR reaction buffer, 1 μl 10 mM dNTP,
0.5 μl 10 mM each primer, 0.5 μl Taq (TaKaRa), 1 μlo ft h e
first-round PCR product, and 19 μl Nuclease-Free Water,
under the same conditions as the first-round PCR, except
reverse transcription step. The PCR products were exam-
ined by electrophoresis with a 3.0% agarose gel.
Preparation of rabbit anti EV71 serum
Rabbit blood collected before immunization was used to
generate negative control sera. Equal volumes of heat-
inactivated EV71 BJ08 strain and complete Freund’s adju-
vant were thoroughly mixed to produce an emulsion.
Then the mixture of 3 ml was injected intramuscularly
into the rear foot pads and inner thigh muscles of a rab-
bits. Boosting immunizations were administered at day 7,
14, 28 and 42 post primary immunizations using the same
method with a exception of replacing Freunds’s complete
adjuvant with incomplete adjuvant. Fourteen days after
the last immunization, blood was collected by cardiac
puncture, and the sera were obtained and stored at -20°C.
Indirect ELISA assay for detecting anti EV71 IgM and IgG
Purified EV71 viral particles were diluted to a final
working concentration (0.01 μg/μl); meanwhile, the syn-
thetic peptides were diluted to a final concentration of
0.1 μg/μl in carbonate buffer (0.1 M pH9.6). These anti-
gen solutions were then coated separately into wells of a
96-well ELISA plate using 50 μl per well. The plate was
kept at 4°C over night, washed once with phosphate buf-
fered saline containing 0.05% Tween-20 (PBST), blocked
for 2 hours with 100 μl per well of casein buffer. Then
50 μl of appropriately diluted serum was added to each
well and incubated at 37°C for 30 min. The plate was
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μl horseradish peroxidase (HRP) conjugated goat anti-
rabbit IgG or goat anti-human IgG or goat anti-human
IgM (all diluted 1:40,000) and incubated for a further 30
min at 37°C, and the plate was wash for 5 times with
PBST. For visualization, 100 μlo fT M Bs u b s t r a t es o l u -
tion was added into each well and incubated at 37°C for
10 mins in a dark situation. The optical densities (OD)
were measured at both 450 nm and 630 nm within 10
min after adding 50 μl2Ms u l f u r i ca c i dt os t o pt h e
reaction. Cutoff value was calculated as mean OD value
of the negative control. If the mean absorbance value of
the negative control was lower than 0.105, cutoff value
was treated as 0.105. Results were expressed in S/CO
value, which was calculated as the ratio of the OD value
obtained with the test sample to the cutoff value deter-
mined concurrently. The S/CO of 5 or higher was
scored as strongly positive reaction; values of 2.1-4.9 as
weakly positive and the S/CO of less than 2.1 was
scored as negative of humoral immune reaction. Goat
anti rabbit IgG-HRP antibody, goat anti human IgG-
HRP antibody and goat anti human IgM-HRP antibody
were purchased from Bethyl Laboratories, USA.
Results
Epitopes stimulating an IgM response in pooled acute
sera
The ELISA results screening pooled acute disease sera
were shown in Figure 1. The majority of human IgM
epitopes were mapped to VP2 and VP3 proteins with
peptides vp2-6, vp2-21, vp2-40, vp2-50, vp3-10, vp3-15
and vp3-24 all judged as strongly positive reaction.
While in VP1 protein, only one peptide (vp1-14) showed
a strong response, and another peptide (vp1-70) exhib-
ited a weakly positive reaction (Figure 1).
Epitope mapping using individual acute stage serum
samples
Individual serum of acute stage disease was screened
(Table 1). The panel of synthetic peptides that had the
Figure 1 ELISA results for peptide screening of EV71 structural proteins with pooled acute disease sera. Eight acute EV71 sera were
collected from infected children, and confirmed as EV71 positive by RT-PCR c a r r i e do u to ne x t r a c t e ds w a bs a m p l e s .E q u a lv o l u m e so fs e r u mf r o me a c h
infected child were mixed and then 80-fold diluted with saline before used for screening the panel of structural protein synthetic peptides. An indirect
ELISA assay was used. The × axis in the histogram shows the synthetic peptides for each structural protein and the y axis indicates the S/CO values.
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individual acute stage serum. A total of 10 human anti-
EV71 IgM epitopes (vp1-14 of VP1;vp2-6, vp2-21, vp2-
40 and, vp2-50 of VP2;vp3-10, vp3-12, vp3-15, vp3-24,
vp3-75 of VP3) were revealed.
Mapping human anti EV71 IgG epitopes in convalescent
sera
The convalescent serum samples from eight infected
individuals were pooled and detected by an indirect
ELISA assay to map IgG epitopes. The results showed a
single strongly positive (vp1-15) and two weakly positive
(vp1-12 and vp1-14) IgG epitopes in VP1 peptide. By
contrast, only scattered weakly positive results were
detected when screening the synthetic peptides of VP2
and VP3 (Figure 2).
Identification of rabbit anti EV71 IgG epitopes
The panels of synthetic peptides were also screened
using a rabbit immunized convalescent sera inactivated
by EV71 BJ08 strain. Pre-immunization serum was used
as a negative control. The results showed that peptides
vp1-14, vp1-31, vp1-54 and vp1-71 in VP1 protein
reacted strongly with the sera, while only weakly positive
reactions were detected for peptides in VP2 and VP3
(Figure 3).
Discussion
The structural protein VP1 has usually been considered
as an indicator of eliciting a protective immune response
after EV71 infection. Consequently, most previous
studies aimed at identifying linear humoral epitopes
for EV71 were focused on this viral protein. Using 95
overlapping synthetic peptides spanning VP1, Foo, et
al. found that two peptides, SP55 (amino acids 162-
177: PESRESLAWQTATNPC) and SP70 (amino acids
208-222: YPTFGEHKQEKDLEYC) were able to induce
neutralizing antibodies against EV71 using an in vitro
microneutralization assay and a neonate mouse chal-
lenge assay [11]. A monoclonal antibody (clone 22A12)
elicited by SP55 and SP70 immunization was found
possessing strong neutralizing activity against EV71
using in vitro neutralization assay [18]. Miao, et al.
developed an EV71/Cox A16-bispecific MAb using
VP1 of EV71, which successfully improved a high-qual-
ity EV identification kit, and could be used as a diag-
nostic tool for identifying a wide range of EVs isolated
from infected patients [19]. VP2 and VP3 were under
certain immune pressure since they are also exposed
outside of the EV71 viral capsid. It is necessary to
explore epitopes on VP2 and VP3. Liu, et al. screened
a panel of 153 overlapping synthetic peptides covering
the entire sequences of VP1, VP2 and VP3 of EV71.
VP2-28 and VP1-43 were recognized by neutralizing
antisera (IgG) generated from rabbit and murine,
respectively [20].
Over the past decade, EV71 outbreak has frequently
occurred in the Asia-Pacific [2-8]. It is the urgent to
understand human IgM and IgG epitopes in order to
provide the basis for the development of vaccines and
diagnostic reagents. In the current study, the strongest
reaction to VP1 peptide vp1-15 was obtained in
Table 1 Tabulated ELISA assay results from screening the panel of EV71 specific synthetic peptides
No.
*
Basic information EV71
Neutralizing
antibody titers
EV71
IgM
test
VP1-
14
VP2-
6
VP2-
21
VP2-
40
VP2-
50
VP3-
10
VP3-
12
VP3-
15
VP3-
24
VP3-
75
Sex Age
(years)
illness
onset
(days)
PCR
dection
OD
value
OD
value
OD
value
OD
value
OD
value
OD
value
OD
value
OD
value
OD
value
OD
value
OD
value
S1 male 5 3 EV71 384 0.819 1.514 0.643 1.343 0.937 1.117 1.496 0.506 1.190 0.803 0.352
S2 female 4 0 EV71 512 0.897 1.304 0.862 0.971 0.809 1.026 1.322 0.583 0.726 0.809 0.256
S3 male 3 0 EV71 24 0.801 1.293 0.894 0.973 0.665 0.937 0.941 0.483 0.812 0.698 0.249
S4 male 4 2 EV71 640 1.009 0.819 0.427 0.535 0.451 0.604 0.758 0.160 0.426 0.327 0.133
S5 male 2 3 EV71 24 0.150 0.332 0.195 0.206 0.196 0.223 0.285 0.101 0.170 0.133 0.068
S6 male 3 1 EV71 128 0.307 0.834 0.440 0.535 0.430 0.540 0.511 0.280 0.445 0.386 0.187
S7 male 5 1 EV71 512 0.622 0.510 0.258 0.164 0.227 0.363 0.331 0.107 0.224 0.253 0.072
S8 female 1.5 0 EV71 16 0.478 0.721 0.521 0.585 0.457 0.562 0.528 0.321 0.373 0.408 0.212
N1 male 29 / / 0.032 0.058 0.057 0.048 0.047 0.048 0.054 0.041 0.054 0.038 0.046
N2 male 34 / / 0.006 0.110 0.085 0.076 0.059 0.086 0.091 0.037 0.072 0.056 0.036
N3 male 30 / / 0.006 0.180 0.151 0.155 0.125 0.141 0.154 0.107 0.099 0.110 0.089
N4 female 50 / / 0.016 0.095 0.053 0.044 0.041 0.061 0.065 0.017 0.053 0.033 0.076
* S1-8 are the acute stage sera samples from infected children. N1-N4 is EV71 negative control sera./: negative by PCR detection or by microneutralization assay
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nized rabbit sera showing positive epitopes reaction
were also primarily located on VP1 protein. The peptide
vp1-14 had the strongest reaction, followed by gradually
decreased reactive peptides vp1-31, vp1-54 and vp1-71.
The positive reaction in various degrees for immunized
rabbit sera and convalescent human sera may reflect dif-
ferent levels of virus infection and inactivated virus
immunization. Overall, these results were consistent
with the previous reports [11,13,20-22].
Detecting an IgM response is important for early
diagnosis of infectious diseases [16,19,23]. However, no
IgM epitopes have been identified for EV71 infection
to date. Although VP1 contains the major identified
epitopes, VP2 and VP3 located on the outside of the
viral particle may also be associated with a protective
immune response occurred upon or after infection.
Consistent with this assumption, the current study
identified several clearly reactive epitopes in VP2 and
VP3 although their reactions were not so strong. Ten
human EV71 IgM epitopes were identified for the first
time, and all identified peptides were positively reacted
to 8 tested sera, which indicated that EV71 infection
may consistently induce multi-epitope anti EV71 IgM
response.
Comparison the distribution of immune-reactive IgM
and IgG epitopes, our data showed that IgM epitopes
were mainly located in VP2 and VP3 capsid proteins,
while only one peptide (vp1-14) was located in VP1 eli-
citing a strong IgM reaction. Another peptide (vp1-15)
located in VP1 protein evoked a strong IgG response
(Table 2).
Figure 2 ELISA results for peptide screening of EV71 structural proteins with pooled convalescent sera. Convalescent sera were collected
from eight children confirmed as EV71 infection by RT-PCR. Equal volumes of serum from each infected child were mixed and then 80-fold
diluted with saline before used for screening the panel of structural protein synthetic peptides. An indirect ELISA assay was used. The × axis in
the histogram shows the synthetic peptides for each structural protein and the y axis indicates the S/CO values.
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human anti EV71 IgM and IgG epitopes to the VP1,
VP2 and VP3 capsid proteins. These results are valuable
for the evaluation of EV71 vaccine immunogenicity and
the development of early diagnostic reagents.
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